


Supplemental Figure-4



Supplemental Figure 4. The anti-inflammatory drug treatment combined with the inhibition of mutant IDH2 induced apoptosis in *IDH2* mutant AML cells by normalizing intracellular arachidonic acid levels *in vitro*

(A) Live cell number of *IDH2* WT or *IDH2* mutant TF-1 cells cultured in cytokine-free condition treated with AG-221, Celecoxib and Zileuton at the indicated combinations *in vitro* (n=3). (B) Percentage of Annexin V⁺ cells in *IDH2* WT and *IDH2* mutant TF-1 cells treated with AG-221, Celecoxib and Zileuton at the indicated combinations for 10 days (n=3). (C) Quantities of intracellular arachidonic acid measured with GC-MS in *IDH2* WT and *IDH2* mutant TF-1 cells treated with AG-221, Celecoxib and Zileuton at the indicated combinations for 10 days. Relative values compared to *IDH2* WT TF-1 cells treated with DMSO were depicted. (n=4-5 from 4-5 independent experiments). (D-E) The relative live cell number to day 0 (D) and the percentage of Annexin V⁺ cells (E) of *IDH2* mutant-overexpressed THP-1 cells treated with AG-221, Celecoxib, and Zileuton at the indicated combinations *in vitro* for 3 days. (n=4). (F) Percentage of Annexin V⁺ cells in *IDH2* WT and *IDH2* mutant TF-1 cells treated with Celecoxib and Zileuton at the indicated combinations for 10 days (n=6 from 2 independent experiments). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ (two-tailed t-test).